EST
REGN icon

EA Series Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

EA Series Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$499K Buy
+694
New +$535K 0.02% 822

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EA Series Trust's REGN Position: Q2 2023 in Review

EA Series Trust opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2023: 694 shares worth $499K. The stake represents 0.02% of the portfolio and ranks #822 among its holdings.

1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • EA Series Trust held 694 shares of Regeneron Pharmaceuticals worth $499K as of Q2 2023.
  • Regeneron Pharmaceuticals was a new EA Series Trust position in Q2 2023.
  • Regeneron Pharmaceuticals made up 0.02% of EA Series Trust's portfolio in Q2 2023, its #822 holding.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.